PHILADELPHIA, Aug. 10, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended June 30, 2009. The net loss (including non-cash expenses) for the fiscal quarter was approximately $3,870,000 or $0.04 per share compared to a loss of approximately $2,802,000 or $0.04 per share for the same period in 2008. The increase in loss was primarily due to 1) non-cash R&D expenses related to employee compensation, 2) bonus awards to certain executives for achieving certain 2008 corporate goals and 3) expenses related to preparing the New Brunswick facility in anticipation of expanded production of Ampligen(r) and Alferon N Injection(r). Cash used in operating activities for the first 6 months was reduced 21.8% relative to the same period in year 2008.
